Daurismo for Newly Diagnosed AML

News
Article

Daurismo Product Image

Daurismo (glasdegib, Pfizer)

Indications: Newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older and have comorbidities that preclude use of intensive induction chemotherapy

Dosage: 100 mg orally, once daily.

Contraindications: None

Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.